News
FBIOP
18.89
+0.21%
0.04
Weekly Report: what happened at FBIOP last week (0713-0717)?
Weekly Report · 5d ago
Weekly Report: what happened at FBIOP last week (0706-0710)?
Weekly Report · 07/13 09:36
Weekly Report: what happened at FBIOP last week (0629-0703)?
Weekly Report · 07/06 09:37
Weekly Report: what happened at FBIOP last week (0622-0626)?
Weekly Report · 06/29 09:35
Journey Medical holds annual shareholder meeting online
PUBT · 06/26 10:03
Fortress Biotech holds annual shareholder meeting
PUBT · 06/23 20:06
Weekly Report: what happened at FBIOP last week (0615-0619)?
Weekly Report · 06/22 09:39
Weekly Report: what happened at FBIOP last week (0608-0612)?
Weekly Report · 06/15 09:40
Weekly Report: what happened at FBIOP last week (0601-0605)?
Weekly Report · 06/08 09:38
Weekly Report: what happened at FBIOP last week (0525-0529)?
Weekly Report · 06/01 09:40
Fortress Biotech: Is It Time To Pay The Deferred Preferred Stock Dividends?
Seeking Alpha · 05/29 21:20
Weekly Report: what happened at FBIOP last week (0518-0522)?
Weekly Report · 05/25 09:42
Journey Medical CEO joins fireside chat at A.G.P. virtual healthcare conference
PUBT · 05/19 20:45
Fortress Biotech CEO joins fireside chat at A.G.P. virtual healthcare conference
PUBT · 05/18 12:32
Weekly Report: what happened at FBIOP last week (0511-0515)?
Weekly Report · 05/18 09:41
Fortress Biotech Q1 net income turns to $137.16 million; revenue rises 22% to $16.04 million
PUBT · 05/14 20:34
Fortress Biotech Q1 net income jumps on PRV sale
Reuters · 05/14 20:20
Journey Medical Q1 revenue rises, adjusted EBITDA turns positive
Reuters · 05/13 20:14
Journey Medical Q1 FY26 net loss narrows to $2.2 million; revenue rises 21% to $16 million
PUBT · 05/13 20:06
Journey Medical Q1 revenue rises 21% to $16 million
PUBT · 05/13 20:02
More
Webull provides a variety of real-time FBIOP stock news. You can receive the latest news about Fortress Biotech Inc through multiple platforms. This information may help you make smarter investment decisions.
About FBIOP
Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.